Regeneron Pharmaceuticals Halts Enrollment in REGN5678 Clinical Trial After Patient Deaths
US-based Regeneron Pharmaceuticals Inc., (NASDAQ: REGN) has reported in its Q2 2023 financial results the...
Insight, China's Pharmaceutical Industry
Fineline Insights, Pharma Clarity